Paul Hastings, Covington Guide Kyverna's Upsized $319M IPO

By Tom Zanki · February 8, 2024, 2:11 PM EST

Cell therapy firm Kyverna Therapeutics Inc. soared 36% in debut trading Thursday after completing an upsized $319 million initial public offering above its price range, guided by Paul Hastings LLP and...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Tom

October 07, 2024
Biotech, Medical Device Firms Prep Three IPOs Totaling $376M
July 10, 2024
Ellenoff-Led SPAC Raises $200M To Pursue Healthcare Merger
May 03, 2024
FTC Requests Additional Info On $16.5B Novo-Catalent Deal
February 07, 2024
REIT Raises $672M IPO At Low End While Insurer Pulls Plans
January 29, 2024
2 Biotech Firms Join IPO Fray With Plans To Raise $211M
January 25, 2024
PE-Backed BrightSpring Prices $693M IPO Below Range
January 24, 2024
Latham, Cooley Steer CG Oncology's Upsized $380M IPO
January 17, 2024
PE-Backed Healthcare Provider BrightSpring Eyes $880M IPO
January 05, 2024
Attys Hopeful For Deals Pickup As JPMorgan Event Kicks Off
January 04, 2024
Deals Rumor Mill: Cigna, Bain Capital, Amazon